COSTA MESA, Calif., Sept. 2, 2014 /PRNewswire-iReach/ -- WCCT Global, a multi-site contract research organization was just recognized as one of the fastest growing companies in America by INC 5000. Over the past few years, the company has undergone significant growth in four main areas: early phase clinical research, late phase global clinical development, anti-viral and vaccine development, and patient recruitment. Over the past 2 years, WCCT Global has successfully participated in over 150 early and late phase clinical trials. In addition, WCCT Global's Global clinical development department has successfully managed numerous data management and medical writing opportunities which has also played a large role in the growth of the company.
WCCT Global's Chief Operating Officer, Jon Rojas stated, "We are pleased to be recognized for our growth by INC 5000. This achievement can mainly be attributed to our talented and devoted staff, nationwide. With our success in clinical research and the strategic partnerships the company has taken, WCCT Global continues to be the CRO of choice for many of our sponsor partners."
Over the next year, this full service CRO will continue to grow and be a leader in the clinical development industry due to their current service offerings and new innovative service offerings. With the recent acquisition of the H1N1 virus and the completion of construction to their dedicated influenza challenge unit, this makes WCCT Global the only commercial influenza challenge unit in the United States. Other areas of continued growth projected for the next year will be with their patient recruitment division called "In-Site" which offers clients a risk free option to only pay for successfully randomized patients. With all of these capabilities, WCCT Global is poised to be contract research organization that will continue to grow year after year.
More about WCCT Global:
WCCT Global is a multi-site, full service pharmaceutical contract research organization (CRO) of outsourced early drug development and late phase services to the pharmaceutical, biotechnology and medical device industries. As a drug development partner, WCCT Global collaborates with domestic and foreign innovator companies who need regulatory, program management, data management, patient recruitment services, and strategic consulting support, with an emphasis on overseeing and executing trials in special disease populations, pediatric populations, ethno-bridging, influenza, and cardiac safety. WCCT has extensive experience with healthy volunteer studies including First-in-Human (FIH), as well as specific therapeutic expertise in Allergy, Asthma, HCV, Ophthalmology, Renal, and Vaccines.
To request more information about WCCT Global's services, CLICK HERE
Media Contact: Matt Miller, WCCT Global, 714.668.1500 ext.2029, Matt.Miller@wcct.com
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
SOURCE WCCT Global